Cephalexin hydrochloride monohydrate (Synonyms: 头孢氨苄单盐酸盐; Cefalexin hydrochloride monohydrate; Cephacillin hydrochloride monohydrate)

目录号: HY-B0200C: Data Sheet 产品使用指南技术支持

Cephalexin (Cefalexin) hydrochloride monohydrate 是一种口服有效的新型半合成头孢菌素抗生素 (antibiotic)，具有广泛的抗菌谱。Cephalexin (Cefalexin) hydrochloride monohydrate 对多种革兰氏阳性和革兰氏阴性细菌具有抗菌活性。Cephalexin (Cefalexin) hydrochloride monohydrate 靶向青霉素结合蛋白 (PBPs)，以抑制细菌细胞壁组装。Cephalexin (Cefalexin) hydrochloride monohydrate 用于肺炎、链球菌性咽喉炎、细菌性心内膜炎等的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Cephalexin hydrochloride monohydrate Chemical Structure

CAS No. : 105879-42-3

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格		是否有货
50 mg		询价
100 mg		询价
250 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Cephalexin hydrochloride monohydrate 的其他形式现货产品:

Cephalexin Cephalexin hydrochloride Cephalexin monohydrate

Customer Review

Other Forms of Cephalexin hydrochloride monohydrate:

MCE 顾客使用本产品发表的 7 篇科研文献

Cephalexin hydrochloride monohydrate 相关产品

•同靶点产品:

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
纯度 & 产品资料
参考文献

生物活性

Cephalexin (Cefalexin) hydrochloride monohydrate is a potent, orally active new semisynthetic cephalosporin antibiotic with a broad antibacterial spectrum. Cephalexin (Cefalexin) hydrochloride monohydrate has antibacterial activity against a wide variety of gram-positive and gram-negative bacteria. Cephalexin (Cefalexin) hydrochloride monohydrate targets penicillin-binding proteins (PBPs) to inhibit bacterial cell wall assembly. Cephalexin (Cefalexin) hydrochloride monohydrate is used for the research of pneumonia, strep throat, and bacterial endocarditis, et al^[1]^[2].

IC₅₀ & Target

β-lactam

体外研究
(In Vitro)

Cephalexin (Cefalexin) hydrochloride monohydrate (10 μg/mL) disrupts polymer peptidoglycan (PG) biogenesis by inactivating enzymes called penicillin-binding proteins (PBPs)^[1].
Cephalexin (Cefalexin) hydrochloride monohydrate inhibits a broad spectrum of grampositive and gram-negative organisms with MIC values of 2, 2, 2, 2, 4, 4.4 and 5.7 μg/mL for Bacillus anthracis, Edwardsiella taFda, Vibrio cholera, Pasteurella multocida, Edwardsiella tarda, Alcaligenes sp and Proteus rettgeri, respectively^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Cephalexin (Cefalexin) hydrochloride monohydrate (0-50 mg/kg; p.o.; for 3.5 hours) has antibacterial activity in male Swiss-Webster mice with infected bacterial^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Swiss-Webster mice with infected bacterial^[2]
Dosage:	0-50 mg/kg
Administration:	Oral administration; for 3.5 hours
Result:	Had antibacterial activity against Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus and several gram-negative species mice.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01912651	University of Michigan	Facial Defect	July 2013	Phase 4
NCT04876131	Murdoch Childrens Research Institute\|Royal Children´s Hospital	Complicated Urinary Tract Infection\|Infection\|Pediatric Infectious Disease	May 30, 2022	Phase 4
NCT04577846	Aga Khan University\|Liaquat National Hospital & Medical College\|Dow University of Health Sciences	Surgical Site Infection	November 1, 2020	Phase 3
NCT01105208	Bayer\|Corporación Bonima S.A. de C.V.	Anti-Infective Agents	March 2010	Phase 1
NCT02100826	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.	Healthy Volunteers	April 2014	Phase 1
NCT01507974	HaEmek Medical Center, Israel	Pregnancy Complications	January 16, 2012	Not Applicable
NCT00729937	National Institute of Allergy and Infectious Diseases (NIAID)	Staphylococcal Infection	April 2009	Phase 2\|Phase 3
NCT01155154	State University of New York - Downstate Medical Center\|Staten Island University Hospital\|Kings County Hospital Center	Simple Hand Lacerations	February 2010	Not Applicable
NCT02123459	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.	Healthy Volunteers	May 2014	Phase 1
NCT04916951	University of Colorado, Denver	Neonatal Infection	July 14, 2021	Phase 1
NCT04834310	University of California, Los Angeles	Surgical Site Infection\|Capsular Contracture Associated With Breast Implant\|Antibiotic Resistant Infection\|Antibiotic Side Effect	April 1, 2021	Phase 4
NCT00234949	Abbott	Mild to Moderate Uncomplicated Skin and Skin Structure Infections	March 2005	Phase 4
NCT02490670	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.	Healthy	July 2015	Phase 1
NCT04297592	Mayo Clinic	Infections Joint Prosthetic\|Overweight or Obesity\|MSSA Colonization\|MRSA\|Chronic Kidney Diseases\|Diabetes\|Autoimmune Diseases\|Inflammatory Disease\|Tobacco Use	June 11, 2020	Phase 4
NCT03736187	Ain Shams University	Surgical Site Infection	April 2019	Not Applicable
NCT01767584	GlaxoSmithKline	Infections, Respiratory Tract	April 6, 2009	Phase 1
NCT04553419	University of British Columbia\|The Hospital for Sick Children	Cystic Fibrosis	July 27, 2020	Phase 3
NCT03357419	Rambam Health Care Campus	Skin Lesion	March 2021	Not Applicable
NCT05020574	University of California, San Francisco\|The Plastic Surgery Foundation	Breast Cancer\|Breast Cancer Female\|Genetic Predisposition to Disease	September 28, 2021	Phase 2
NCT00187759	University of California, San Francisco	Soft Tissue Infections	November 2004	Not Applicable
NCT01631617	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)\|National Institutes of Health Clinical Center (CC)	Eczema\|Dermatitis\|Skin Diseases, Genetic\|Dermatitis, Atopic\|Skin Diseases	September 18, 2012	Phase 2
NCT05852262	Ottawa Hospital Research Institute\|Network of Canadian Emergency Researchers (NCER)\|The Ottawa Hospital Academic Medical Association	Cellulitis	August 1, 2023	Phase 4
NCT03148444	Kaplan Medical Center	Infection, Bacterial\|Pacemaker Complication	June 1, 2017	Phase 4
NCT01194115	University of Cincinnati	Surgical Site Infection in Obese Women Undergoing C-section	September 2010	Not Applicable
NCT05664568	Western Sydney Local Health District\|Centre Of Research Excellence in Tuberculosis Control	Tuberculosis, Pulmonary	March 15, 2023	Phase 2
NCT01595529	National Institute of Allergy and Infectious Diseases (NIAID)	Urinary Tract Infection	May 18, 2012	Phase 2
NCT03187106	The University of Texas Medical Branch, Galveston	Surgical Site Infection	August 1, 2017	Phase 1
NCT04538053	Murdoch Childrens Research Institute	Bone Infection\|Septic Arthritis\|Bone and Joint Infection\|Osteomyelitis	June 1, 2021	Phase 4
NCT01767571	GlaxoSmithKline	Infections, Respiratory Tract	January 30, 2011	Phase 1
NCT04194216	Stanford University\|Washington University School of Medicine\|Vanderbilt University School of Medicine\|University of Washington\|Duke University\|Harvard University\|University of Kansas Medical Center\|University of Cincinnati\|Loma Linda University	Nasal Obstruction\|Nasal Surgical Procedures	May 20, 2020	Phase 3
NCT00003824	SWOG Cancer Research Network\|National Cancer Institute (NCI)	Bladder Cancer	April 1999	Phase 3
NCT01073540	Bayer\|Corporación Bonima S.A. de C.V.	Anti-Infective Agents	September 2009	Phase 1
NCT02569866	Federal University of São Paulo\|Universidade do Vale do Sapucai	Surgical Site Infection	November 2014	Phase 2
NCT00352612	Aaron Chen\|Thrasher Research Fund\|Johns Hopkins University	Staphylococcal Infection\|Abscess\|Staphylococcal Skin Infection\|Folliculitis	September 2006	Phase 4
NCT00676130	Brigham and Women´s Hospital	Cellulitis	May 2007	Not Applicable
NCT02014558	Astellas Pharma Global Development, Inc.\|Astellas Pharma Inc	Acute Myeloid Leukemia	October 9, 2013	Phase 1\|Phase 2
NCT02145338	Newcastle-upon-Tyne Hospitals NHS Trust\|NHS Health Technology Assessment Programme\|Newcastle University\|Glasgow Caledonian University\|University of Aberdeen\|Cambridge University Hospitals NHS Foundation Trust\|North Bristol NHS Trust\|University of Southampton	Urinary Tract Infections, Recurrent	September 2013	Phase 4
NCT01073553	Bayer\|Corporación Bonima S.A. de C.V.	Anti-Infective Agents	October 2009	Phase 1
NCT01029782	Kelowna General Hospital\|Canadian Society of Hospital Pharmacists\|Capital Health, Canada\|Interior Health Authority, Canada	Cellulitis	May 2010	Phase 2
NCT02123446	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.	Healthy Volunteers	April 2014	Phase 1
NCT01400867	Forest Laboratories\|AstraZeneca	Infections, Pediatrics	December 2011	Phase 2\|Phase 3
NCT01002911	Population Health Research Institute	Arrythmias	December 2009	Phase 3
NCT04580472	Carilion Clinic	Surgical Site Infection	October 1, 2020	Phase 4
NCT03802552	University of Colorado, Denver	Osteomyelitis\|Septic Arthritis\|Pyomyositis	May 1, 2019	Phase 1
NCT05274672	Baylor Research Institute\|Albert Einstein Healthcare Network	Benign Prostatic Hyperplasia\|Urinary Tract Infections	March 1, 2022	Phase 4
NCT04471246	Ottawa Hospital Research Institute\|The Ottawa Hospital Academic Medical Association\|Canadian Association of Emergency Physicians	Cellulitis	August 16, 2021	Phase 4
NCT01767532	GlaxoSmithKline	Infections, Respiratory Tract	January 30, 2011	Phase 1
NCT02911662	Saint Joseph Mercy Health System	Bacteriuria (Asymptomatic) in Pregnancy	September 2016	Not Applicable
NCT02123472	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.	Healthy Volunteers	May 2014	Phase 1

分子量

401.87

Formula

C₁₆H₂₀ClN₃O₅S

CAS 号

105879-42-3

中文名称

头孢氨苄单盐酸盐

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料

Data Sheet (538 KB) 产品使用指南 (1538 KB)

参考文献

[1]. Cho H, et, al. Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery. Cell. 2014 Dec 4;159(6):1300-11. [Content Brief]

[2]. Buck RE, et, al. Cefadroxil, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1977 Feb;11(2):324-30. [Content Brief]

Cephalexin hydrochloride monohydrate 相关分类

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量		浓度		体积		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)	×	体积 _(start)	=	浓度 _(final)	×	体积 _(final)
	×		=		×
C1		V1		C2		V2

Keywords:

Cephalexin hydrochloride105879-42-3Cefalexin hydrochlorideCephacillin hydrochloride头孢氨苄单盐酸盐Penicillin-binding protein (PBP)AntibioticBacterialgram-positive bacteriagram-negative bacteriapenicillin-binding proteinscell wall assemblyInhibitorinhibitorinhibit

您最近查看的产品:

Cephalexin hydrochloride monohydrate

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

Cephalexin hydrochloride monohydrate (Synonyms: 头孢氨苄单盐酸盐; Cefalexin hydrochloride monohydrate; Cephacillin hydrochloride monohydrate)

Customer Review

Other Forms of Cephalexin hydrochloride monohydrate:

MCE 顾客使用本产品发表的 7 篇科研文献

Cephalexin hydrochloride monohydrate 相关产品

•同靶点产品:

查看 Antibiotic 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Cephalexin hydrochloride monohydrate 相关分类

摩尔计算器

稀释计算器

The molarity calculator equation

The dilution calculator equation

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Cephalexin hydrochloride monohydrate (Synonyms: 头孢氨苄单盐酸盐; Cefalexin hydrochloride monohydrate; Cephacillin hydrochloride monohydrate)

Customer Review

Other Forms of Cephalexin hydrochloride monohydrate:

Cephalexin hydrochloride monohydrate 相关抗体

MCE 顾客使用本产品发表的 7 篇科研文献

Cephalexin hydrochloride monohydrate 相关产品

•同靶点产品:

查看 Antibiotic 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Cephalexin hydrochloride monohydrate 相关抗体:

Cephalexin hydrochloride monohydrate 相关分类

摩尔计算器

稀释计算器

The molarity calculator equation

The dilution calculator equation

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z